Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials

Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting pr...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Breast Cancer 2012-01, Vol.2012 (2012), p.117-123
Main Authors: Amos, Keith D., Anders, Carey K., Adamo, Barbara
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a502t-1e00de6eee6b56a47c2b248a0290bf811e8c7441a5e0398f4c3ac3e90e5ce8aa3
cites cdi_FETCH-LOGICAL-a502t-1e00de6eee6b56a47c2b248a0290bf811e8c7441a5e0398f4c3ac3e90e5ce8aa3
container_end_page 123
container_issue 2012
container_start_page 117
container_title International Journal of Breast Cancer
container_volume 2012
creator Amos, Keith D.
Anders, Carey K.
Adamo, Barbara
description Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.
doi_str_mv 10.1155/2012/385978
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_629ae2c50bbf4d27ba3a99a21a2acc76</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><airiti_id>P20151207002_201212_201709210015_201709210015_117_123</airiti_id><doaj_id>oai_doaj_org_article_629ae2c50bbf4d27ba3a99a21a2acc76</doaj_id><sourcerecordid>963493023</sourcerecordid><originalsourceid>FETCH-LOGICAL-a502t-1e00de6eee6b56a47c2b248a0290bf811e8c7441a5e0398f4c3ac3e90e5ce8aa3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhiMEolXpiTMoNyRQ6NiOY5tDpbKCUmlVOLRna-JMtl5lncVJFvHvcTdlxZ7wZWzPo8cfb5a9ZvCRMSkvODB-IbQ0Sj_LTjkYKATT5vlhruAkOx-GNaQhmRCVepmdcF5WzOjyNLu-i37bUXFLKxz9jvLPkXAY8wUGR_FTfhXy-22DI-V9yG-px2Y97TAkoPPBO-zyJMBueJW9aFOh86d6lt1__XK3-FYsv1_fLK6WBUrgY8EIoKGKiKpaVlgqx2teagRuoG41Y6SdKkuGkkAY3ZZOoBNkgKQjjSjOspvZ2_S4ttvoNxh_2x693W_0cWUxjt51ZCtukLiTUNdt2XBVo0BjkDPk6Jyqkutydm2nekONozBG7I6kx53gH-yq31nBVfpLkwTvngSx_znRMNqNHxx1HQbqp8GaSpRGABeJ_DCTLvbDEKk9nMLAPgZpH4O0c5CJfvvvxQ7s39gS8H4GHnxo8Jf_j-3NDFNCqMUDXFbKaJb6y7mPPvrR23U_xZAytD-SRTIOCoDvjWxfFBjOILWOF4wpy9JT_wCMaMMY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>963493023</pqid></control><display><type>article</type><title>Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials</title><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><creator>Amos, Keith D. ; Anders, Carey K. ; Adamo, Barbara</creator><contributor>Chu, Quyen D.</contributor><creatorcontrib>Amos, Keith D. ; Anders, Carey K. ; Adamo, Barbara ; Chu, Quyen D.</creatorcontrib><description>Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.</description><identifier>ISSN: 2090-3170</identifier><identifier>EISSN: 2090-3189</identifier><identifier>DOI: 10.1155/2012/385978</identifier><identifier>PMID: 22461984</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Review</subject><ispartof>International Journal of Breast Cancer, 2012-01, Vol.2012 (2012), p.117-123</ispartof><rights>Copyright © 2012 Keith D. Amos et al.</rights><rights>Copyright © 2012 Keith D. Amos et al. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a502t-1e00de6eee6b56a47c2b248a0290bf811e8c7441a5e0398f4c3ac3e90e5ce8aa3</citedby><cites>FETCH-LOGICAL-a502t-1e00de6eee6b56a47c2b248a0290bf811e8c7441a5e0398f4c3ac3e90e5ce8aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270519/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270519/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22461984$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Chu, Quyen D.</contributor><creatorcontrib>Amos, Keith D.</creatorcontrib><creatorcontrib>Anders, Carey K.</creatorcontrib><creatorcontrib>Adamo, Barbara</creatorcontrib><title>Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials</title><title>International Journal of Breast Cancer</title><addtitle>Int J Breast Cancer</addtitle><description>Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.</description><subject>Review</subject><issn>2090-3170</issn><issn>2090-3189</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkU1v1DAQhiMEolXpiTMoNyRQ6NiOY5tDpbKCUmlVOLRna-JMtl5lncVJFvHvcTdlxZ7wZWzPo8cfb5a9ZvCRMSkvODB-IbQ0Sj_LTjkYKATT5vlhruAkOx-GNaQhmRCVepmdcF5WzOjyNLu-i37bUXFLKxz9jvLPkXAY8wUGR_FTfhXy-22DI-V9yG-px2Y97TAkoPPBO-zyJMBueJW9aFOh86d6lt1__XK3-FYsv1_fLK6WBUrgY8EIoKGKiKpaVlgqx2teagRuoG41Y6SdKkuGkkAY3ZZOoBNkgKQjjSjOspvZ2_S4ttvoNxh_2x693W_0cWUxjt51ZCtukLiTUNdt2XBVo0BjkDPk6Jyqkutydm2nekONozBG7I6kx53gH-yq31nBVfpLkwTvngSx_znRMNqNHxx1HQbqp8GaSpRGABeJ_DCTLvbDEKk9nMLAPgZpH4O0c5CJfvvvxQ7s39gS8H4GHnxo8Jf_j-3NDFNCqMUDXFbKaJb6y7mPPvrR23U_xZAytD-SRTIOCoDvjWxfFBjOILWOF4wpy9JT_wCMaMMY</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Amos, Keith D.</creator><creator>Anders, Carey K.</creator><creator>Adamo, Barbara</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AFFIF</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120101</creationdate><title>Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials</title><author>Amos, Keith D. ; Anders, Carey K. ; Adamo, Barbara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a502t-1e00de6eee6b56a47c2b248a0290bf811e8c7441a5e0398f4c3ac3e90e5ce8aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amos, Keith D.</creatorcontrib><creatorcontrib>Anders, Carey K.</creatorcontrib><creatorcontrib>Adamo, Barbara</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>قاعدة دراسات المرأة - e-Marefa Women Studies</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International Journal of Breast Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amos, Keith D.</au><au>Anders, Carey K.</au><au>Adamo, Barbara</au><au>Chu, Quyen D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials</atitle><jtitle>International Journal of Breast Cancer</jtitle><addtitle>Int J Breast Cancer</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>2012</volume><issue>2012</issue><spage>117</spage><epage>123</epage><pages>117-123</pages><issn>2090-3170</issn><eissn>2090-3189</eissn><abstract>Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>22461984</pmid><doi>10.1155/2012/385978</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-3170
ispartof International Journal of Breast Cancer, 2012-01, Vol.2012 (2012), p.117-123
issn 2090-3170
2090-3189
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_629ae2c50bbf4d27ba3a99a21a2acc76
source Wiley-Blackwell Open Access Titles; PubMed Central
subjects Review
title Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A21%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triple-Negative%20Breast%20Cancer:%20An%20Update%20on%20Neoadjuvant%20Clinical%20Trials&rft.jtitle=International%20Journal%20of%20Breast%20Cancer&rft.au=Amos,%20Keith%20D.&rft.date=2012-01-01&rft.volume=2012&rft.issue=2012&rft.spage=117&rft.epage=123&rft.pages=117-123&rft.issn=2090-3170&rft.eissn=2090-3189&rft_id=info:doi/10.1155/2012/385978&rft_dat=%3Cproquest_doaj_%3E963493023%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a502t-1e00de6eee6b56a47c2b248a0290bf811e8c7441a5e0398f4c3ac3e90e5ce8aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=963493023&rft_id=info:pmid/22461984&rft_airiti_id=P20151207002_201212_201709210015_201709210015_117_123&rfr_iscdi=true